Can We Slow Aging?
What Human Clinical Trials Really Show
From calorie restriction to new therapies, what do human trials actually demonstrate about slowing aging?
Every week brings headlines announcing that the cure for aging is around the corner. But when we strip away sensationalist claims and examine the rigorous gold standard—peer-reviewed human randomized clinical trials—what does the data actually demonstrate?
The CALERIE Trial: The Gold Standard in Human Calorie Restriction
For decades, calorie restriction was proven to dramatically extend lifespan in yeast, worms, flies, and rodents. The NIH-funded CALERIE trial (Comprehensive Assessment of Long-term Effects of Reducing Intake of Energy) sought to answer whether this translates to non-obese, healthy humans.
Participants subjected to a sustained 12% to 14% caloric restriction over two years exhibited marked reductions in systemic inflammation, profound improvements in cardiometabolic risk profiles, and a statistically significant deceleration in DunedinPACE biological aging rates.
“The CALERIE trial provided unequivocal proof of principle: biological aging in humans can be measured and statistically decelerated through metabolic modulation.”
- Sustained moderate caloric restriction slows the biological pace of aging in healthy adult humans.
- Repurposed pharmaceutical candidates (mTOR inhibitors, SGLT2i, GLP-1RA) show consistent cardiometabolic and neuroprotective benefits.
- Human longevity trials require surrogate biomarker endpoints validated by regulatory authorities.
Pharmaceutical Contenders: Metformin, Rapamycin, and SGLT2 Inhibitors
Among candidate longevity pharmacotherapies, mTOR inhibition via rapamycin holds the most robust mammalian lifespan extension record. Human clinical trials are currently investigating low-dose, intermittent rapalogs to stimulate autophagy and enhance immune senescence without immunosuppressive side effects.
Concurrently, the TAME (Targeting Aging with Metformin) initiative, spearheaded by the American Federation for Aging Research (AFAR), is designed to establish whether metformin can delay the onset of multi-morbid chronic conditions in humans, thereby establishing aging as a treatable medical indication under regulatory bodies.
Senolytics in Human Clinical Testing
Senolytics—agents designed to selectively induce apoptosis in senescent 'zombie' cells—have entered Phase I and II human trials for conditions ranging from idiopathic pulmonary fibrosis to Alzheimer's disease and osteoarthritis. Combinations such as Dasatinib plus Quercetin (D+Q) and natural flavonoids like Fisetin are demonstrating clearance of senescent cell burdens and reductions in circulating SASP biomarkers.
While long-term safety and optimal dosing schedules remain under rigorous clinical investigation, the transition from bench to bedside is officially underway.
This article is for educational purposes only and is not medical advice. Consult a licensed healthcare physician before starting any clinical protocol.
